Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242056 | 0.87 | HSD11B1 (0.49) | HSD11B1L3MBTL1DDB1CRBNTACR3 | |
| SCHEMBL7421674 | 0.83 | L3MBTL1 (0.47) | HSD11B1L3MBTL1DDB1CRBNTACR3 | |
| SCHEMBL7421678 | 0.83 | L3MBTL1 (0.47) | HSD11B1L3MBTL1DDB1CRBNTACR3 | |
| SCHEMBL28152480 | 0.83 | HSD11B1 (0.52) | HSD11B1L3MBTL1ROCK2DDB1CRBN | |
| SCHEMBL27504767 | 0.81 | STS (0.48) | HSD11B1 | |
| SCHEMBL3741416 | 0.81 | STS (0.48) | HSD11B1 | |
| SCHEMBL22450119 | 0.79 | HSD11B1 (0.51) | HSD11B1L3MBTL1ALDH1A1 | |
| SCHEMBL28152541 | 0.79 | HSD11B1 (0.58) | HSD11B1L3MBTL1ROCK2DDB1CRBN | |
| SCHEMBL5108569 | 0.78 | ACE (0.65) | HSD11B1KMT2A | |
| SCHEMBL6654051 | 0.77 | HSD11B1 (0.56) | HSD11B1L3MBTL1ROCK2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, MTOR | HSD11B1 2385/4885L3MBTL1 1483/4885ROCK2 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.